InBriefs

New data reveal residual unmet needs in young SMA patients treated with gene therapy and suggest further potential of using SPINRAZA®

Ionis amends CARDIO-TTRansform study of eplontersen

Phase 2 Study of olezarsen published in European Heart Journal

Key learnings from GENERATION HD1 study of tominersen highlighted at CHDI 2022

Ionis initiates HALOS clinical study of Angelman syndrome

Topline results of Phase 2 clinical study support continued development of Cimdelirsen designed to treat uncontrolled acromegaly

ASCEND study to evaluate a higher dose of Ionis-discovered nusinersen in SMA patients who had less than optimal response to Evrysdi

Ionis launches ‘Ion-ARPA’ initiative with an eye toward revolutionizing drug discovery – again

Ionis expands distribution agreement with Sobi to include TEGSEDI® in North America

ION537 will be evaluated at MD Anderson in a Phase 1 study of patients with liver and head and neck cancers

New England Journal of Medicine: Results of Phase 1/2 study of tofersen, an antisense oligonucleotide, demonstrate proof-of-concept and proof-of-biology of the Ionis-created therapy to treat SOD1 familial ALS

Lancet Gastroenterology and Hepatology: innovative antisense therapy shows potential to be safe and efficacious for the treatment of NAFLD and NASH

Lancet Neurology: Teens and adults on SPINRAZA® showed clinically meaningful improvement in motor function

Ionis Statement on COVID-19

Ionis and partner highlight tominersen (formerly known as IONIS-HTTRx and RG6042) data at annual Huntington’s disease drug discovery conference